A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Lyell Immunopharma, Inc.
National Cancer Institute (NCI)
Genmab
Genmab
Genmab
Canadian Cancer Trials Group
Novartis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
SWOG Cancer Research Network
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
University of Chicago
Regeneron Pharmaceuticals
Allogene Therapeutics
Fred Hutchinson Cancer Center
Essen Biotech
Mayo Clinic
Regeneron Pharmaceuticals
University of Michigan Rogel Cancer Center
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
Celgene
Fred Hutchinson Cancer Center
Gilead Sciences
M.D. Anderson Cancer Center
Celgene
Sana Biotechnology
Massachusetts General Hospital
University of Arizona
Case Comprehensive Cancer Center
Celgene
Masonic Cancer Center, University of Minnesota
Thomas Jefferson University
Gilead Sciences
City of Hope Medical Center
University of Maryland, Baltimore
Jonsson Comprehensive Cancer Center
Universität des Saarlandes
Acepodia Biotech, Inc.
Roswell Park Cancer Institute
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Adicet Therapeutics
Peking University Cancer Hospital & Institute
City of Hope Medical Center
Janssen Research & Development, LLC
City of Hope Medical Center
University of Liverpool